Erasca
dose cohorts | Erasca
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
33 of 41
Related slides by other companies
Chimerix
Investor Presentation
August 2023
dose pediatric and adult tumors dose trials enrolling in parallel for adult and pediatric tumors response reported by investigator from early cohort without mutation once weekly dose is expected to intensify to three consecutive days per week national institutes of health pacific | Chimerix
Snowflake
Investor Event
June 2023
assumes ramp and stable expansion rates | Snowflake
Aeglea BioTherapeutics
Investor Presentation
October 2023
spy phase clinical trial design | Aeglea BioTherapeutics
Chimerix
Investor Presentation
August 2023
oral brain penetrant antagonist agonist second generation designed to expand to new indications efficacy in cell culture and central nervous system and other tumor models oral dose trials ongoing in cancers response reported by investigator in early dose cohort for a patient in recurrent non | Chimerix
Other recent decks by Erasca
See all presentations (4 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
IPO
July 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io